CURRICULUM VITAE

Roel GW Verhaak, PhD

**Version date:** 11/2/2023

**Proposed for:** Appointment Professor, Traditional track with Tenure Department of Neurosurgery Yale School of Medicine

**Term:** On a continuing basis beginning 04/01/2023

**School:** Yale School of Medicine

**Education:**

2000 - 2004 MSc, Biomedical Sciences, Radboud University, Nijmegen, the Netherlands

2006 - 2006 PhD, Erasmus University Medical Center, Rotterdam, the Netherlands

2007 - 2010 Postdoctoral Fellow, Laboratory of Matthew Meyerson, Dana-Farber Cancer Institute/Broad Institute of MIT and Harvard, Cambridge MA

# Career/Academic Appointments:

2002 - 2003 Software engineer, Dalicon BV, Nijmegen, the Netherlands

2006 - 2007 Research Scientist, Laboratory of Peter JM Valk, Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands

2010 - Computational biologist, Laboratory of Matthew Meyerson, Broad Institute of MIT and Harvard, Cambridge, MA.

2010 - 2015 Assistant professor, Department of Bioinformatics and Computational Biology, UT MD Anderson Cancer Center, Houston, TX

2013 - 2015 Assistant professor, Department of Genomic Medicine, UT MD Anderson Cancer Center, Houston, TX

2015 - 2016 Associate professor, Department of Bioinformatics and Computational Biology (primary), Department of Genomic Medicine (affiliate), UT MD Anderson Cancer Center, Houston, TX

2016 - 2023 Professor and Associate Director for Computational Biology, The Jackson Laboratory for Genomic Medicine, Farmington, CT

2017 - 2023 Adjunct professor, Department of Genetics and Genomic Sciences, Department of Neurosurgery, UConn Health

2018 - 2022 Scientific co-founder and scientific advisor board member, Boundless Bio, San Diego, CA

2021 - 2022 Stellanova Therapeutics, scientific advisory board member

2021 - Professor, Department of Neurosurgery, Amsterdam University Medical Center, Amsterdam,

the Netherlands (10% effort)

2021 - 2023 Florine Dechenes Roux Endowed Chair for Genomics and Computational Biology

2022 - NeuroTrials, Inc/Ivy Brain Tumor Center scientific advisory board member

2023 – present Professor, Department of Neurosurgery, Yale School of Medicine

**Administrative Positions:**

2016 - Associate Director of Computational Biology, Jackson Laboratory for Genomic Medicine

2017 - 2022 Program Leader, Jackson Laboratory Cancer Center (NCI-designated)

2018 - Chair, Scientific Advisory Committee, Jackson Laboratory

2021 - 2023 Organizer, JAX-GM Distinguished Seminar Series

**Public & Institutional Service**

2016 - 2018 Terry Fox New Frontiers Program Project Grant (PI: Sheila Singh, MD, PhD), Scientific Advisory Board member. Grant reviewer for foundations including the Flemish Cancer Association, AIRC Foundation for Cancer Research, Brain Tumor Charity (UK), Brain Research UK (UK), Cancer Research UK (UK), the Dutch Cancer Society (Netherlands), KiKa (Netherlands), American Brain Tumor Association, CORE (Luxembourg), Polish Science Foundation (Poland), Fondazione Pisa (Italy), and others. Manuscript reviewer for journals including Cell, Nature, New England Journal of Medicine, Cancer Cell, Nature Genetics, Nature Medicine, Nature Methods, Nature Biotechnology, Nature Communications, Cell Stem Cell, and others. Editorial Board member of Neuro-Oncology and Genes, Chromosomes and Cancer.

2017 Member, Scientific Advisory Committee, Jackson Laboratory

2017 National Institute of Biomedical Imaging and Bioengineering (NIBIB), Multiscale Modeling program study section, ad hoc member

2017 Sidra Medical and Research Center, Doha, Qatar, External Advisory Board member

2018 National Cancer Institute Cancer Genetics study section, ad hoc member

2018 National Cancer Institute ZRG1 Special Emphasis Panel study section, ad hoc member

2019 Hartwig Medical Foundation, Scientific Advisory Board, member

2019 National Cancer Institute Cancer Genetics program study section, ad hoc member

2019 External Scientific Advisory Committee, Brain Cancer SPORE, University of Alabama in Birmingham, AL

2019 National Cancer Institute Integrated Canine Data Commons, Steering Committee member

2020 National Cancer Institute CSR Special Emphasis Panel study section, ad hoc member

2020 National Cancer Institute Cancer Genetics study section, ad hoc member

2021 External Scientific Advisory Committee, Brain Cancer SPORE, UT MD Anderson Cancer 2022 FY22 Rare Cancer Research Program for the Department of Defense Congressionally Directed Medical Research Programs, Neurological Cancer panel, ad hoc member.

2021 National Cancer Institute ZRG1 Special Emphasis Panel study section, ad hoc member

Center

2021 National Cancer Institute ZRG1 Special Emphasis Panel study section, ad hoc member

Center

2021 Cancer Research UK, Expert Review Panel

2021 National Cancer Institute ZCA1 Special Emphasis Panel study section, ad hoc member

2022 National Cancer Institute, SBIR Contract Review Panel, ad hoc member

2022 National Cancer Institute Cancer Genetics study section, ad hoc member

**Professional Honors & Recognition:**

***International/National/Regional***

2006 Netherlands Genomics Initiative Fellowship

2008 - 2010 Fundamental and pre-clinical fellowship, Dutch Cancer Society KWF

2011 Wilson S. Stone Memorial Award at MD Anderson's Symposia on Cancer Research

2013 Pediatric Brain Tumor Foundation, Peter Steck Memorial Award

2014 Adult Basic Science Award, Society for Neuro-Oncology Meeting 2014

2015 Finalist, Robert M. Chamberlain Distinguished Mentor Award

2015 Brain Tumor Epidemiology Consortium meeting, Rochester, MN (keynote)

2015 International Symposium on Clinical and Basic Investigation in Glioblastoma, Toledo, Spain(keynote)

2016 AAAS Martin and Rose Wachtel Cancer Research Award

2016 Agilent Early Career Professor Award

2017 Christopher Davidson Forum, Wash U School of Medicine, St. Louis, MO (keynote)

2018 Five Points Lecture, New York Genome Center, New York, NY

2018 Meeting of the Society for Neuro-Oncology of China, Changsha, China (keynote)

2018 Daniel den Hoed Visiting Professor, Erasmus University Medical Center, Rotterdam, the Netherlands

2019 21st Annual Labatt Brain Tumor Research Centre Academic Lectureship, The Hospital for Sick Children, Toronto, Canada

2019 Highly cited researcher; Web of Science

2020 Inter-SPORE Brain Cancer Meeting, Chicago, IL (keynote)

2020 Meeting of the Society for Neuro-Oncology in China, Nanjing, China (keynote)\*

2020 The Michael Rossman Brain Tumor Lectureship, 19th Biennial Canadian Neuro-Oncology meeting, Ottawa, Canada (keynote)\*

2020 American Association of Neuropathology 96th Annual Meeting Presidential Symposium speaker, Monterey, CA (virtual)

2020 Highly cited researcher; Web of Science

2021 122nd meeting of the British Neuropathological Society, keynote (virtual)

2021 26th Annual Meeting and Education Day of the Society for Neuro-Oncology, keynote

2022 6th Annual Translational and Transformative Informatics Symposium of the UAB Informatics Institute and Center for Clinical and Translational Science, keynote (virtual)

2022 2022 Joint Distinguished Lecture Speaker, Yale Stem Cell Center Retreat, West Haven, CT

2022 Scandinavian Society of Neuro-oncology (SNOG) 2022 symposium, Helsinki, Finland

2022 Highly cited researcher; Web of Science

# Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated with Yale:

2004 4th VIB Microarray Users Group Meeting, Brussels, Belgium

2004 CBSB Symposium on Bioinformatics in microarrays research, Amsterdam, the Netherlands

2005 Department of Hemato-oncology, Beth Israel Deaconess Medical Center, Boston, MA

2008 NUS Cancer Research Centre of Excellence, Singapore

2009 The Cancer Genome Atlas meeting on glioblastoma, San Diego, CA

2010 Computational Biology Center, Memorial Sloan Kettering Center, New York, NY

2010 Netherlands Cancer Institute

2010 Department of Bioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, TX

2011 Center for Molecular Medicine, Vienna, Austria

2011 “New roles for the EGFR Family in Cancer” Symposium, MD Anderson Cancer Center, Houston, TX

2011 Grand Rounds, University of Michigan, Ann Arbor, MI

2011 NRCI Cancer Conference 2011, Liverpool, UK

2012 Department of Genetics, Baylor College of Medicine, Houston, TX

2012 NCI Clinical Proteomic Technologies for Cancer meeting, Houston, TX

2012 1st Brazilian Genome Conference, Foz do Iguacu, Brazil

2012 58th Brazilian Congress of Genetics, Foz do Iguacu, Brazil

2012 21st Annual Symposium on Molecular Pathology, Troy, MI

2012 The Cancer Genome Atlas Pan-cancer comparison meeting, Santa Cruz, CA

2012 Memorial Sloan-Kettering Brain Tumor Center, New York, NY

2012 Ontario Cancer Institute, Toronto, CA

2013 The Cancer Genome Atlas Steering Committee meeting, Bethesda, MD

2013 Symposia on Cancer Research 2013: Genomic Medicine, Houston,

2013 Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands

2013 NCI Workshop: Correlating imaging phenotypes with genomic signatures, Bethesda, MD

2014 ASCO Genitourinary Cancers Symposium, San Francisco, CA

2014 VU Medical Center, Amsterdam, The Netherlands

2014 Einstein Circle GBM Biology, Berlin, Germany

2014 Department of Neurological Surgery, University of California San Francisco, San Francisco, CA

2015 Seminars in Oncology, Dana-Farber Cancer Institute, Boston, MA

2015 Cedar-Sinai Medical Center, Los Angeles, CA

2015 Spanish National Cancer Research Centre (CNIO), Madrid, Spain

2015 American Brain Tumor Association Alumni Network meeting, Chicago, IL

2015 International Symposium on Clinical and Basic Investigation in Glioblastoma, Toledo, Spain(keynote)

2015 Brain Tumor Epidemiology Consortium meeting, Rochester, MN (keynote)

2015 Society for Neuro-Oncology 2015 Annual Meeting, San Antonio, TX

2015 Samsung Medical Center, Seoul, South Korea

2016 Cold Spring Harbor Laboratory Brain Tumor Course, Huntington, NY

2016 German Cancer Center, Heidelberg, Germany

2016 Samsung Medical Center, Seoul, South-Korea

2016 Radboud University Medical Center, Nijmegen, the Netherlands

2016 VU Medical Center, Amsterdam, the Netherlands

2016 Dartmouth College, Hanover, NH

2017 Annual Society for Neuro-Oncology meeting, San Francisco, CA

2017 Luxembourg Institute of Health (LIH), Luxembourg, Luxembourg

2017 Christopher Davidson Forum, Wash U School of Medicine, St. Louis, MO (keynote)

2017 Jackson Laboratory, 26th Short Course on Human Cancer, Bar Harbor, ME

2017 World Federation of Neuro-Oncology Societies, Zurich, Switzerland

2017 American Association for Cancer Research, Washington, DC

2017 CNIO Frontier meeting: Primary and Secondary Brain Tumors, Madrid, Spain

2017 Seminars in Oncology, Dana-Farber Cancer Institute, Boston, MA

2017 Yale School of Public Health, Yale University, New Haven, CT

2017 Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

2018 Oligodendroglioma workshop, Neuro-Oncological Branch, NIH Clinical Center, Washington, DC

2018 Brain Cancer Strategy Workshop by ABC2, Washington, DC

2018 American Brain Tumor Association Alumni Network meeting, Chicago, IL

2018 Cold Spring Harbor Laboratory Brain Tumor Course, Huntington, NY

2018 24th Conference of the International Union of Biochemistry and Molecular Biology, Seoul, South Korea

2018 Ewha Women’s University, Seoul, South Korea

2018 Cancer Research UK Brain Tumor Conference 2018, London, UK

2018 Meeting of the Society for Neuro-Oncology of China, Changsha, China (keynote)

2018 Five Points Lecture, New York Genome Center, New York, NY

2019 Frontiers in Precision Medical Science, KAIST, Daejeon, South-Korea

2019 Molecular Analysis for Personalized Therapy Congress 2019, London, UK

2019 Berlin Brain Tumor Meeting, Berlin, Germany

2019 Glioblastoma Workshop, Banbury Center, Cold Spring Harbor Laboratory, Lloyd Harbor, NY

2019 Department of Neurosurgery, University of Alabama Birmingham, Birmingham, AL

2020 Brigham and Women’s/Harvard Oncology, webinar

2020 Brain Tumor Charity, webinar

2020 Barrow Neuroscience Institute, Grand Rounds, Phoenix, AZ

2021 Third Annual Cutting Edge in Neuroscience Symposium, UConn Health (virtual)

2021 Nederlandse Vereniging voor Radio-Biology Symposium (virtual)

2021 Australian Brain Cancer Research Alliance Research Symposium, keynote speaker

2021 International Conference of The Genetics Society of Korea (virtual)

2021 Hong Kong and Shanghai Brain Consortium (virtual)

2021 Dana-Farber Cancer Institute Seminars in Oncology, webinar

2021 Philadelphia Coalition for a Cure Symposium (virtual)

2021 European Association of Neuro-Oncology Annual Meeting (virtual)

2021 Missouri University of Science and Technology and Southern Illinois University, Edwardsville, MO, webinar

2021 Biotechnology Center of the Federal University of Rio Grande do Sul, Brazil, webinar.

2021 Romanian Society of Bioinformatics, webinar

2021 Royal Society of Medicine Medical Genetics section (UK), webinar

2021 UT Health San Antonio, webinar

2021 University of Cambridge Cancer Centre Conference (keynote), webinar

2021 AACR Annual Meeting, Educational session, webinar

2021 The Institute of Cancer Research, London, webinar

2021 Dana-Farber/Harvard Cancer Center, Grand Rounds in Neuro-Oncology, webinar

2021 Royal College of Surgeons of Dublin, webinar

2021 First UCSF Brain Tumor Center Retreat, webinar

2021 NCI Neuro-Oncological Branch, webinar

2022 Memorial Sloan-Kettering Computational Oncology seminar series

2022 Society for Neuro-Oncology in Latin America 2022 (virtual)

2022 Forbeck Forum on The Genesis and Function of Extrachromosomal Oncogene Amplifications in Cancer, Denver, CO

2022 American Association for Cancer Research, session chair and invited speaker, New Orleans, LA

2022 Yale Clinical Neuroscience Grand Rounds (virtual)

2022 Memorial Sloan Kettering Radiation Oncology Grand Rounds (virtual)

2022 Cooper Health Neurosurgery Grand Rounds (virtual)

2022 European Society for Medical Oncology, Paris, France

2022 Netherlands Cancer Institute, Amsterdam, the Netherlands

2022 University of Virginia Comprehensive Cancer Center Michael Weber Symposium, Charlottesville, VA

2022 14th International Frontiers in Cancer Science Conference, Singapore.

2023 Dartmouth College, Lebanon, NH

2023 Cleveland Clinic, Cleveland, OH

2023 University of Texas Southwestern, Dallas, TX

2023 Mark Foundation Workshop on CIN, London, UK

***Journals:***

***Patent and patent applications***

1. WO US US20180330049A1. Methods for classification of glioma. Iavarone A, Noushmehr H, **Verhaak RGW**.
2. WO US US20190360029A1. A method of targeting patient-specific oncogenes in extrachromosomal DNA to treat glioblastoma. **Verhaak R**, Kim H, DeCarvalho A, Mikkelsen T.
3. WO US US20210062250A1: Extrachromosomal DNA Labeling. Yi E, **Verhaak R**.
4. WO2020223309A1: Extrachromosomal DNA identification and methods of use. Wei C, Zhu Y, **Verhaak R.**
5. Pending: A genomic signature of radiation therapy damage. Kocakavuk E, Barthel F, **Verhaak R.**

***Research Support***

1. Extrachromosomal DNA as a Targetable Mechanism in Glioblastoma (**Verhaak**). NIH/NCI R01 CA237208. 12/01/19-11/30/24.
2. Familial GBM (Personal Philanthropic Donation, total committed amount $1M, to the lab of Roel Verhaak, Wells Family). 2021-2024.
3. OPTimIzing Engagement in discovery of molecular evolution of low-grade glioma (OPTIMUM). (Claus, Verhaak, Kwan). NIH/NCI U2C CA252979. 09/01/2021-08/31/2026
4. Understanding the cellular and functional changes in the immune tumor microenvironment of glioblastoma during progression and treatments (Charest, Boussiotis, Verhaak). NIH/NCI R01CA271601. 04/17/23-03/31/28.
5. eDynamic – Yale University (Verhaak). CRUK Cancer Grand Challenges CGCATF-2021/100016. 06/01/22-05/31/27
6. eDynamic – Yale University (Verhaak). NIH/NCI OT2-CA278649. 06/01/22-05/31/27.

**Bibliography:**

†Corresponding author

\* Contributed equally

¥ Member of manuscript committee

*Google Scholar Citation Page:* [*http://scholar.google.com/citations?user=qXdBk-gAAAAJ&hl=en&oi=ao*](http://scholar.google.com/citations?user=qXdBk-gAAAAJ&hl=en&oi=ao)

1. Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, Liu W, Yang JY, Yoshihara K, Li J, Ling S, Seviour EG, Ram PT, Minna JD, Diao L, Tong P, Heymach JV, Hill SM, Dondelinger F, Städler N, Byers LA, Meric-Bernstam F, Weinstein JN, Broom BM, **Verhaak RG**, Liang H, Mukherjee S, Lu Y, Mills GB. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun. 2014 May 29;5:3887. doi: 10.1038/ncomms4887. Erratum in: Nat Commun. 2015;6:4852. PMID: 24871328; PMCID: PMC4109726.
2. Heffernan AE, Wu Y, Benz LS, **Verhaak RGW**, Kwan BM, Claus EB. Quality of life after surgery for lower grade gliomas. **Cancer. 2023 Aug 20.** doi: 10.1002/cncr.34980. Epub ahead of print. PMID: 37599093.
3. Claus EB, **Verhaak RGW.** Targeting IDH in Low-Grade Glioma. N Engl J Med. **2023 Aug** 17;389(7):655-659. doi: 10.1056/NEJMe2305602. PMID: 37585633.
4. Kocakavuk E, Johnson KC, Sabedot TS, Reinhardt HC, Noushmehr H, Verhaak RGW. Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas. Neuro Oncol. 2023 Sep 5;25(9):1721-1723. doi: 10.1093/neuonc/noad095. PMID: 37329568; PMCID: PMC10479907.
5. Luebeck J, Ng AWT, Galipeau PC, Li X, Sanchez CA, Katz-Summercorn AC, Kim H, Jammula S, He Y, Lippman SM, **Verhaak RGW,** Maley CC, Alexandrov LB, Reid BJ, Fitzgerald RC, Paulson TG, Chang HY, Wu S, Bafna V, Mischel PS. Extrachromosomal DNA in the cancerous transformation of Barrett's oesophagus. Nature. 2023 Apr;616(7958):798-805. doi: 10.1038/s41586-023-05937-5. Epub **2023 Apr 12**. PMID: 37046089; PMCID: PMC10132967.
6. Akdemir KC, Le VT, Chandran S, Li Y, **Verhaak RG**, Beroukhim R, Campbell PJ, Chin L, Dixon JR, Futreal PA; PCAWG Structural Variation Working Group; PCAWG Consortium. Author Correction: Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nat Genet. **2023 Jun;**55(6):1079. doi: 10.1038/s41588-023-01318-w. Erratum for: Nat Genet. 2020 Mar;52(3):294-305. PMID: 36944735; PMCID: PMC10260394.
7. Yeo AT, Shah R, Aliazis K, Pal R, Xu T, Zhang P, Rawal S, Rose CM, Varn FS, Appleman VA, Yoon J, Varma H, Gygi SP, **Verhaak RGW**, Boussiotis VA, Charest A. Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma. Cancer Immunol Res. 2023 May 3;11(5):629-645. doi: 10.1158/2326-6066.CIR-22-0655. PMID: 36881002; PMCID: PMC10155040.
8. Schuster AL, Crossnohere NL, Bachini M, Blair CK, Carpten JD, Claus EB, Colditz GA, Ding L, Drake BF, Fields RC, Janeway KA, Kwan BM, Lenz HJ, Ma Q, Mishra SI, Paskett ED, Rebbeck TR, Ricker C, Stern MC, Sussman AL, Tiner JC, Trent JM, **Verhaak RG**, Wagle N, Willman C, Bridges JF; Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. Priorities to Promote Participant Engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. Cancer Epidemiol Biomarkers Prev. 2023 Apr 3;32(4):487-495. doi: 10.1158/1055-9965.EPI-22-0356. PMID: 36791345; PMCID: PMC10068438.
9. Ajaib S, Lodha D, Pollock S, Hemmings G, Finetti MA, Gusnanto A, Chakrabarty A, Ismail A, Wilson E, Varn FS, Hunter B, Filby A, Brockman AA, McDonald D, **Verhaak RGW**, Ihrie RA, Stead LF. GBMdeconvoluteR accurately infers proportions of neoplastic and immune cell populations from bulk glioblastoma transcriptomics data. Neuro Oncol. 2023 Jul 6;25(7):1236-1248. doi: 10.1093/neuonc/noad021. PMID: 36689332; PMCID: PMC10326489.
10. Al-Holou WN, Wang H, Ravikumar V, Shankar S, Oneka M, Fehmi Z, **Verhaak RG**, Kim H, Pratt D, Camelo-Piragua S, Speers C, Wahl DR, Hollon T, Sagher O, Heth JA, Muraszko KM, Lawrence TS, de Carvalho AC, Mikkelsen T, Rao A, Rehemtulla A. Subclonal evolution and expansion of spatially distinct THY1-positive cells is associated with recurrence in glioblastoma. Neoplasia. 2023 Feb;36:100872. doi: 10.1016/j.neo.2022.100872. Epub 2023 Jan 6. PMID: 36621024; PMCID: PMC9841165.
11. White K, Connor K, Meylan M, Bougoüin A, Salvucci M, Bielle F, O'Farrell AC, Sweeney K, Weng L, Bergers G, Dicker P, Ashley DM, Lipp ES, Low JT, Zhao J, Wen P, Prins R, Verreault M, Idbaih A, Biswas A, Prehn JHM, Lambrechts D, Arijs I, Lodi F, Dilcan G, Lamfers M, Leenstra S, Fabro F, Ntafoulis I, Kros JM, Cryan J, Brett F, Quissac E, Beausang A, MacNally S, O'Halloran P, Clerkin J, Bacon O, Kremer A, Chi Yen RT, Varn FS, **Verhaak RGW**, Sautès-Fridman C, Fridman WH, Byrne AT. Identification, validation, and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy. Ann Oncol. 2023 Mar;34(3):300-314. doi: 10.1016/j.annonc.2022.11.008. Epub 2022 Dec 6. PMID: 36494005.
12. Pecorino LT, **Verhaak RGW**, Henssen A, Mischel PS. Extrachromosomal DNA (ecDNA): an origin of +tumor heterogeneity, genomic remodeling, and drug resistance. Biochem Soc Trans. 2022 Dec 16;50(6):1911-1920. doi: 10.1042/BST20221045. PMID: 36355400; PMCID: PMC9788557.
13. Zhang ZY, Ding Y, Ezhilarasan R, Lhakhang T, Wang Q, Yang J, Modrek AS, Zhang H, Tsirigos A, Futreal A, Draetta GF, Verhaak RGW, Sulman EP. Lineage-coupled clonal capture identifies clonal evolution mechanisms and vulnerabilities of BRAFV600E inhibition resistance in melanoma. Cell Discov. 2022 Oct 6;8(1):102. doi: 10.1038/s41421-022-00462-7. PMID: 36202798; PMCID: PMC9537441.
14. Wu L, Wu W, Zhang J, Zhao Z, Li L, Zhu M, Wu M, Wu F, Zhou F, Du Y, Chai RC, Zhang W, Qiu X, Liu Q, Wang Z, Li J, Li K, Chen A, Jiang Y, Xiao X, Zou H, Srivastava R, Zhang T, Cai Y, Liang Y, Huang B, Zhang R, Lin F, Hu L, Wang X, Qian X, Lv S, Hu B, Zheng S, Hu Z, Shen H, You Y, **Verhaak RGW,** Jiang T, Wang Q. Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma. Cancer Discov. 2022 Dec 2;12(12):2820-2837. doi: 10.1158/2159-8290.CD-22-0196. PMID: 36122307; PMCID: PMC9716251.
15. Modrek AS, Eskilsson E, Ezhilarasan R, Wang Q, Goodman LD, Ding Y, Zhang ZY, Bhat KPL, Le TT, Barthel FP, Tang M, Yang J, Long L, Gumin J, Lang FF, **Verhaak RGW**, Aldape KD, Sulman EP. PDPN marks a subset of aggressive and radiation-resistant glioblastoma cells. Front Oncol. 2022 Aug 10;12:941657. doi: 10.3389/fonc.2022.941657. PMID: 36059614; PMCID: PMC9434399.
16. Yi E, Chamorro González R, Henssen AG, **Verhaak RGW.** Extrachromosomal DNA amplifications in cancer. Nat Rev Genet. 2022 Dec;23(12):760-771. doi: 10.1038/s41576-022-00521-5. Epub 2022 Aug 11. PMID: 35953594; PMCID: PMC9671848.
17. Varn FS, Johnson KC, Martinek J, Huse JT, Nasrallah MP, Wesseling P, Cooper LAD, Malta TM, Wade TE, Sabedot TS, Brat D, Gould PV, Wöehrer A, Aldape K, Ismail A, Sivajothi SK, Barthel FP, Kim H, Kocakavuk E, Ahmed N, White K, Datta I, Moon HE, Pollock S, Goldfarb C, Lee GH, Garofano L, Anderson KJ, Nehar-Belaid D, Barnholtz-Sloan JS, Bakas S, Byrne AT, D'Angelo F, Gan HK, Khasraw M, Migliozzi S, Ormond DR, Paek SH, Van Meir EG, Walenkamp AME, Watts C, Weiss T, Weller M, Palucka K, Stead LF, Poisson LM, Noushmehr H, Iavarone A, **Verhaak RGW**; GLASS Consortium. Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell. 2022 Jun 9;185(12):2184-2199.e16. doi: 10.1016/j.cell.2022.04.038. Epub 2022 May 31. PMID: 35649412; PMCID: PMC9189056.
18. Yamaguchi M, Nakaoka H, Suda K, Yoshihara K, Ishiguro T, Yachida N, Saito K, Ueda H, Sugino K, Mori Y, Yamawaki K, Tamura R, Revathidevi S, Motoyama T, Tainaka K, **Verhaak RGW**, Inoue I, Enomoto T. Spatiotemporal dynamics of clonal selection and diversification in normal endometrial epithelium. Nat Commun. 2022 Feb 17;13(1):943. doi: 10.1038/s41467-022-28568-2. PMID: 35177608; PMCID: PMC8854701.
19. Shen E, Van Swearingen AED, Price MJ, Bulsara K, **Verhaak RGW,** Baëta C, Painter BD, Reitman ZJ, Salama AKS, Clarke JM, Anders CK, Fecci PE, Goodwin CR, Walsh KM. A Need for More Molecular Profiling in Brain Metastases. Front Oncol. 2022 Jan 25;11:785064. doi: 10.3389/fonc.2021.785064. PMID: 35145903; PMCID: PMC8821807.
20. Yi E, Gujar AD, Guthrie M, Kim H, Zhao D, Johnson KC, Amin SB, Costa ML, Yu Q, Das S, Jillette N, Clow PA, Cheng AW, **Verhaak RGW**. Live-Cell Imaging Shows Uneven Segregation of Extrachromosomal DNA Elements and Transcriptionally Active Extrachromosomal DNA Hubs in Cancer. Cancer Discov. 2022 Feb;12(2):468-483. doi: 10.1158/2159-8290.CD-21-1376. Epub 2021 Nov 24. PMID: 34819316; PMCID: PMC8831456.
21. Johnson KC, Anderson KJ, Courtois ET, Gujar AD, Barthel FP, Varn FS, Luo D, Seignon M, Yi E, Kim H, Estecio MRH, Zhao D, Tang M, Navin NE, Maurya R, Ngan CY, Verburg N, de Witt Hamer PC, Bulsara K, Samuels ML, Das S, Robson P, **Verhaak RGW**. Single-cell multimodal glioma analyses identify epigenetic regulators of cellular plasticity and environmental stress response. Nat Genet. 2021 Oct;53(10):1456-1468. doi: 10.1038/s41588-021-00926-8. Epub 2021 Sep 30. PMID: 34594038; PMCID: PMC8570135.
22. Barekatain Y, Ackroyd JJ, Yan VC, Khadka S, Wang L, Chen KC, Poral AH, Tran T, Georgiou DK, Arthur K, Lin YH, Satani N, Ballato ES, Behr EI, deCarvalho AC, **Verhaak RGW**, de Groot J, Huse JT, Asara JM, Kalluri R, Muller FL. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine. Nat Commun. 2021 Jul 9;12(1):4228. doi: 10.1038/s41467-021-24240-3. PMID: 34244484; PMCID: PMC8270912.
23. Johnson KC, **Verhaak RGW**. Serum cell-free DNA epigenetic biomarkers aid glioma diagnostics and monitoring. Neuro Oncol. 2021 Sep 1;23(9):1423-1424. doi: 10.1093/neuonc/noab146. PMID: 34139018; PMCID: PMC8408867.
24. Verburg N, Barthel FP, Anderson KJ, Johnson KC, Koopman T, Yaqub MM, Hoekstra OS, Lammertsma AA, Barkhof F, Pouwels PJW, Reijneveld JC, Rozemuller AJM, Beliën JAM, Boellaard R, Taylor MD, Das S, Costello JF, Vandertop WP, Wesseling P, de Witt Hamer PC, **Verhaak RGW.** Spatial concordance of DNA methylation classification in diffuse glioma. Neuro Oncol. 2021 Dec 1;23(12):2054-2065. doi: 10.1093/neuonc/noab134. PMID: 34049406; PMCID: PMC8643482.
25. Kocakavuk E, Anderson KJ, Varn FS, Johnson KC, Amin SB, Sulman EP, Lolkema MP, Barthel FP, **Verhaak RGW**. Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer. Nat Genet. 2021 Jul;53(7):1088-1096. doi: 10.1038/s41588-021-00874-3. Epub 2021 May 27. PMID: 34045764; PMCID: PMC8483261.
26. Zhu Y, Gujar AD, Wong CH, Tjong H, Ngan CY, Gong L, Chen YA, Kim H, Liu J, Li M, Mil-Homens A, Maurya R, Kuhlberg C, Sun F, Yi E, deCarvalho AC, Ruan Y, **Verhaak RGW**, Wei CL. Oncogenic extrachromosomal DNA functions as mobile enhancers to globally amplify chromosomal transcription. Cancer Cell. 2021 May 10;39(5):694-707.e7. doi: 10.1016/j.ccell.2021.03.006. Epub 2021 Apr 8. PMID: 33836152; PMCID: PMC8119378.
27. Kim Y, Varn FS, Park SH, Yoon BW, Park HR, Lee C, Verhaak RGW, Paek SH. Perspective of mesenchymal transformation in glioblastoma. Acta Neuropathol Commun. 2021 Mar 24;9(1):50. doi: 10.1186/s40478-021-01151-4. PMID: 33762019; PMCID: PMC7992784.
28. Gromeier M, Brown MC, Zhang G, Lin X, Chen Y, Wei Z, Beaubier N, Yan H, He Y, Desjardins A, Herndon JE 2nd, Varn FS, **Verhaak RG**, Zhao J, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Lipp ES, Nair SK, Khasraw M, Peters KB, Randazzo D, Sampson JH, McLendon RE, Bigner DD, Ashley DM. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nat Commun. 2021 Jan 13;12(1):352. doi: 10.1038/s41467-020-20469-6. PMID: 33441554; PMCID: PMC7806846.
29. Park SY, Mittal S, Dong J, Jeong K, Martinez-Ledesma E, Piao Y, Khan S, Henry V, **Verhaak RG**, Majd N, Balasubramaniyan V, de Groot JF. Depletion of CLK2 sensitizes glioma stem-like cells to PI3K/mTOR and FGFR inhibitors. Am J Cancer Res. 2020 Nov 1;10(11):3765-3783. PMID: 33294266; PMCID: PMC7716149.
30. Penas-Prado M, Wu J, Cahill DP, Brat DJ, Costello JF, Kluetz PG, Cairncross JG, van den Bent M, **Verhaak RGW**, Aboud O, Burger P, Chang SM, Cordova C, Huang RY, Rowe LS, Taphoorn MJB, Gilbert MR, Armstrong TS; NCI-CONNECT Oligodendroglioma Workshop. Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Oligodendroglioma Workshop. Neurooncol Adv. 2019 Dec 6;2(1):vdz048. doi: 10.1093/noajnl/vdz048. PMID: 33289010; PMCID: PMC7212866.
31. Akdemir KC, Le VT, Kim JM, Killcoyne S, King DA, Lin YP, Tian Y, Inoue A, Amin SB, Robinson FS, Nimmakayalu M, Herrera RE, Lynn EJ, Chan K, Seth S, Klimczak LJ, Gerstung M, Gordenin DA, O'Brien J, Li L, Deribe YL, **Verhaak RG,** Campbell PJ, Fitzgerald R, Morrison AJ, Dixon JR, Andrew Futreal P. Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure. Nat Genet. 2020 Nov;52(11):1178-1188. doi: 10.1038/s41588-020-0708-0. Epub 2020 Oct 5. PMID: 33020667; PMCID: PMC8350746.
32. Sa JK, Chang N, Lee HW, Cho HJ, Ceccarelli M, Cerulo L, Yin J, Kim SS, Caruso FP, Lee M, Kim D, Oh YT, Lee Y, Her NG, Min B, Kim HJ, Jeong DE, Kim HM, Kim H, Chung S, Woo HG, Lee J, Kong DS, Seol HJ, Lee JI, Kim J, Park WY, Wang Q, Sulman EP, Heimberger AB, Lim M, Park JB, Iavarone A, **Verhaak RGW**, Nam DH. Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma. Genome Biol. 2020 Aug 26;21(1):216. doi: 10.1186/s13059-020-02140-x. PMID: 32847614; PMCID: PMC7448990.
33. Kim H, Nguyen NP, Turner K, Wu S, Gujar AD, Luebeck J, Liu J, Deshpande V, Rajkumar U, Namburi S, Amin SB, Yi E, Menghi F, Schulte JH, Henssen AG, Chang HY, Beck CR, Mischel PS, Bafna V, **Verhaak RGW**. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nat Genet. 2020 Sep;52(9):891-897. doi: 10.1038/s41588-020-0678-2. Epub 2020 Aug 17. PMID: 32807987; PMCID: PMC7484012.
34. Oldrini B, Vaquero-Siguero N, Mu Q, Kroon P, Zhang Y, Galán-Ganga M, Bao Z, Wang Z, Liu H, Sa JK, Zhao J, Kim H, Rodriguez-Perales S, Nam DH, **Verhaak RGW**, Rabadan R, Jiang T, Wang J, Squatrito M. MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas. Nat Commun. 2020 Aug 4;11(1):3883. doi: 10.1038/s41467-020-17717-0. PMID: 32753598; PMCID: PMC7403430.
35. Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Le Rhun E, Lim M, Mehta MP, Mellinghoff IK, Minniti G, Nathanson D, Platten M, Preusser M, Roth P, Sanson M, Schiff D, Short SC, Taphoorn MJB, Tonn JC, Tsang J, **Verhaak RGW**, von Deimling A, Wick W, Zadeh G, Reardon DA, Aldape KD, van den Bent MJ. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020 Aug 17;22(8):1073-1113. doi: 10.1093/neuonc/noaa106. PMID: 32328653; PMCID: PMC7594557.
36. Amin SB, Anderson KJ, Boudreau CE, Martinez-Ledesma E, Kocakavuk E, Johnson KC, Barthel FP, Varn FS, Kassab C, Ling X, Kim H, Barter M, Lau CC, Ngan CY, Chapman M, Koehler JW, Long JP, Miller AD, Miller CR, Porter BF, Rissi DR, Mazcko C, LeBlanc AK, Dickinson PJ, Packer RA, Taylor AR, Rossmeisl JH Jr, Woolard KD, Heimberger AB, Levine JM, **Verhaak RGW**. Comparative Molecular Life History of Spontaneous Canine and Human Gliomas. Cancer Cell. 2020 Feb 10;37(2):243-257.e7. doi: 10.1016/j.ccell.2020.01.004. PMID: 32049048; PMCID: PMC7132629.
37. Akdemir KC, Le VT, Chandran S, Li Y, **Verhaak RG**, Beroukhim R, Campbell PJ, Chin L, Dixon JR, Futreal PA; PCAWG Structural Variation Working Group; PCAWG Consortium. Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nat Genet. 2020 Mar;52(3):294-305. doi: 10.1038/s41588-019-0564-y. Epub 2020 Feb 5. Erratum in: Nat Genet. 2023 Jun;55(6):1079. PMID: 32024999; PMCID: PMC7058537.
38. Anderson KJ, Tan AC, Parkinson J, Back M, Kastelan M, Newey A, Brewer J, Wheeler H, Hudson AL, Amin SB, Johnson KC, Barthel FP, **Verhaak RGW**, Khasraw M. Molecular and clonal evolution in recurrent metastatic gliosarcoma. Cold Spring Harb Mol Case Stud. 2020 Feb 3;6(1):a004671. doi: 10.1101/mcs.a004671. PMID: 31896544; PMCID: PMC6996521.
39. Wu S, Gao F, Zheng S, Zhang C, Martinez-Ledesma E, Ezhilarasan R, Ding J, Li X, Feng N, Multani A, Sulman EP, **Verhaak RG**, de Groot JF, Heffernan TP, Yung WKA, Koul D. *EGFR* Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. Clin Cancer Res. 2020 Mar 15;26(6):1395-1407. doi: 10.1158/1078-0432.CCR-19-2549. Epub 2019 Dec 18. PMID: 31852834.
40. Vaubel RA, Tian S, Remonde D, Schroeder MA, Mladek AC, Kitange GJ, Caron A, Kollmeyer TM, Grove R, Peng S, Carlson BL, Ma DJ, Sarkar G, Evers L, Decker PA, Yan H, Dhruv HD, Berens ME, Wang Q, Marin BM, Klee EW, Califano A, LaChance DH, Eckel-Passow JE, **Verhaak RG,** Sulman EP, Burns TC, Meyer FB, O'Neill BP, Tran NL, Giannini C, Jenkins RB, Parney IF, Sarkaria JN. Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma. Clin Cancer Res. 2020 Mar 1;26(5):1094-1104. doi: 10.1158/1078-0432.CCR-19-0909. Epub 2019 Dec 18. PMID: 31852831; PMCID: PMC7056576.
41. Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran EJ, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Gould PV, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Reifenberger G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Tabatabai G, Van Meir EG, Watts C, Weller M, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, **Verhaak RGW;** GLASS Consortium. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019 Dec;576(7785):112-120. doi: 10.1038/s41586-019-1775-1. Epub 2019 Nov 20. PMID: 31748746; PMCID: PMC6897368.
42. Wu S, Turner KM, Nguyen N, Raviram R, Erb M, Santini J, Luebeck J, Rajkumar U, Diao Y, Li B, Zhang W, Jameson N, Corces MR, Granja JM, Chen X, Coruh C, Abnousi A, Houston J, Ye Z, Hu R, Yu M, Kim H, Law JA, **Verhaak RGW**, Hu M, Furnari FB, Chang HY, Ren B, Bafna V, Mischel PS. Circular ecDNA promotes accessible chromatin and high oncogene expression. Nature. 2019 Nov;575(7784):699-703. doi: 10.1038/s41586-019-1763-5. Epub 2019 Nov 20. PMID: 31748743; PMCID: PMC7094777.
43. Draaisma K, Chatzipli A, Taphoorn M, Kerkhof M, Weyerbrock A, Sanson M, Hoeben A, Lukacova S, Lombardi G, Leenstra S, Hanse M, Fleischeuer R, Watts C, McAbee J, Angelopoulos N, Gorlia T, Golfinopoulos V, Kros JM, **Verhaak RGW**, Bours V, van den Bent MJ, McDermott U, Robe PA, French PJ. Molecular Evolution of *IDH* Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. J Clin Oncol. 2020 Jan 1;38(1):81-99. doi: 10.1200/JCO.19.00367. Epub 2019 Nov 19. PMID: 31743054.
44. Stead LF, **Verhaak RGW**. Doomed from the TERT? A Two-Stage Model of Tumorigenesis in IDH-Wild-Type Glioblastoma. Cancer Cell. 2019 Apr 15;35(4):542-544. doi: 10.1016/j.ccell.2019.03.009. PMID: 30991024.
45. Zheng S, Alfaro-Munoz K, Wei W, Wang X, Wang F, Eterovic AK, Shaw KRM, Meric-Bernstam F, Fuller GN, Chen K, **Verhaak RG**, Mills GB, Yung WKA, Weathers SP, de Groot JF. Prospective Clinical Sequencing of Adult Glioma. Mol Cancer Ther. 2019 May;18(5):991-1000. doi: 10.1158/1535-7163.MCT-18-1122. Epub 2019 Mar 29. PMID: 30926639; PMCID: PMC6497568.
46. **Verhaak RGW**, Bafna V, Mischel PS. Extrachromosomal oncogene amplification in tumour pathogenesis and evolution. Nat Rev Cancer. 2019 May;19(5):283-288. doi: 10.1038/s41568-019-0128-6. PMID: 30872802; PMCID: PMC7168519.
47. Spiteri I, Caravagna G, Cresswell GD, Vatsiou A, Nichol D, Acar A, Ermini L, Chkhaidze K, Werner B, Mair R, Brognaro E, **Verhaak RGW**, Sanguinetti G, Piccirillo SGM, Watts C, Sottoriva A. Evolutionary dynamics of residual disease in human glioblastoma. Ann Oncol. 2019 Mar 1;30(3):456-463. doi: 10.1093/annonc/mdy506. PMID: 30452544; PMCID: PMC6442656.
48. Lee JK, Liu Z, Sa JK, Shin S, Wang J, Bordyuh M, Cho HJ, Elliott O, Chu T, Choi SW, Rosenbloom DIS, Lee IH, Shin YJ, Kang HJ, Kim D, Kim SY, Sim MH, Kim J, Lee T, Seo YJ, Shin H, Lee M, Kim SH, Kwon YJ, Oh JW, Song M, Kim M, Kong DS, Choi JW, Seol HJ, Lee JI, Kim ST, Park JO, Kim KM, Song SY, Lee JW, Kim HC, Lee JE, Choi MG, Seo SW, Shim YM, Zo JI, Jeong BC, Yoon Y, Ryu GH, Kim NKD, Bae JS, Park WY, Lee J, **Verhaak RGW**, Iavarone A, Lee J, Rabadan R, Nam DH. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nat Genet. 2018 Oct;50(10):1399-1411. doi: 10.1038/s41588-018-0209-6. Epub 2018 Sep 27. PMID: 30262818; PMCID: PMC8514738.
49. Lee JK, Liu Z, Sa JK, Shin S, Wang J, Bordyuh M, Cho HJ, Elliott O, Chu T, Choi SW, Rosenbloom DIS, Lee IH, Shin YJ, Kang HJ, Kim D, Kim SY, Sim MH, Kim J, Lee T, Seo YJ, Shin H, Lee M, Kim SH, Kwon YJ, Oh JW, Song M, Kim M, Kong DS, Choi JW, Seol HJ, Lee JI, Kim ST, Park JO, Kim KM, Song SY, Lee JW, Kim HC, Lee JE, Choi MG, Seo SW, Shim YM, Zo JI, Jeong BC, Yoon Y, Ryu GH, Kim NKD, Bae JS, Park WY, Lee J, **Verhaak RGW**, Iavarone A, Lee J, Rabadan R, Nam DH. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nat Genet. 2018 Oct;50(10):1399-1411. doi: 10.1038/s41588-018-0209-6. Epub 2018 Sep 27. PMID: 30262818; PMCID: PMC8514738.
50. Menghi F, Barthel FP, Yadav V, Tang M, Ji B, Tang Z, Carter GW, Ruan Y, Scully R, **Verhaak RGW**, Jonkers J, Liu ET. The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations. Cancer Cell. 2018 Aug 13;34(2):197-210.e5. doi: 10.1016/j.ccell.2018.06.008. Epub 2018 Jul 12. PMID: 30017478; PMCID: PMC6481635.
51. Akgül S, Li Y, Zheng S, Kool M, Treisman DM, Li C, Wang Y, Gröbner S, Ikenoue T, Shen Y, Camelo-Piragua S, Tomasek G, Stark S, Guduguntla V, Gusella JF, Guan KL, Pfister SM, **Verhaak RGW**, Zhu Y. Opposing Tumor-Promoting and -Suppressive Functions of Rictor/mTORC2 Signaling in Adult Glioma and Pediatric SHH Medulloblastoma. Cell Rep. 2018 Jul 10;24(2):463-478.e5. doi: 10.1016/j.celrep.2018.06.050. PMID: 29996106; PMCID: PMC6116735.
52. Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, **Verhaak RGW**, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB. Profiles of brain metastases: Prioritization of therapeutic targets. Int J Cancer. 2018 Dec 1;143(11):3019-3026. doi: 10.1002/ijc.31624. Epub 2018 Oct 9. PMID: 29923182; PMCID: PMC6235694.
53. deCarvalho AC, Kim H, Poisson LM, Winn ME, Mueller C, Cherba D, Koeman J, Seth S, Protopopov A, Felicella M, Zheng S, Multani A, Jiang Y, Zhang J, Nam DH, Petricoin EF, Chin L, Mikkelsen T, **Verhaak RGW**. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. Nat Genet. 2018 May;50(5):708-717. doi: 10.1038/s41588-018-0105-0. Epub 2018 Apr 23. PMID: 29686388; PMCID: PMC5934307.
54. Barthel FP, Wesseling P, **Verhaak RGW**. Reconstructing the molecular life history of gliomas. Acta Neuropathol. 2018 May;135(5):649-670. doi: 10.1007/s00401-018-1842-y. Epub 2018 Apr 3. PMID: 29616301; PMCID: PMC5904231
55. GLASS Consortium. Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. Neuro Oncol. 2018 Jun 18;20(7):873-884. doi: 10.1093/neuonc/noy020. PMID: 29432615; PMCID: PMC6280138.
56. Tamura R, Yoshihara K, Saito T, Ishimura R, Martínez-Ledesma JE, Xin H, Ishiguro T, Mori Y, Yamawaki K, Suda K, Sato S, Itamochi H, Motoyama T, Aoki Y, Okuda S, Casingal CR, Nakaoka H, Inoue I, **Verhaak RGW,** Komatsu M, Enomoto T. Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions. Oncogenesis. 2018 Jan 23;7(1):4. doi: 10.1038/s41389-017-0018-2. PMID: 29358619; PMCID: PMC5833787.
57. Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Gabriel Sauvé CE, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2018 Jan 8;33(1):152. doi: 10.1016/j.ccell.2017.12.012. Erratum for: Cancer Cell. 2017 Jul 10;32(1):42-56.e6. PMID: 29316430; PMCID: PMC5892424.
58. Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT; TCGA Research Network; Cherniack AD, Benz C, Mills GB, **Verhaak RGW**, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2018 Jan 8;33(1):151. doi: 10.1016/j.ccell.2017.12.013. Erratum for: Cancer Cell. 2017 Aug 14;32(2):204-220.e15. PMID: 29316429.
59. Hu X, Wang Q, Tang M, Barthel F, Amin S, Yoshihara K, Lang FM, Martinez-Ledesma E, Lee SH, Zheng S, **Verhaak RGW.** TumorFusions: an integrative resource for cancer-associated transcript fusions. Nucleic Acids Res. 2018 Jan 4;46(D1):D1144-D1149. doi: 10.1093/nar/gkx1018. PMID: 29099951; PMCID: PMC5753333.
60. Ong DST, Hu B, Ho YW, Sauvé CG, Bristow CA, Wang Q, Multani AS, Chen P, Nezi L, Jiang S, Gorman CE, Monasterio MM, Koul D, Marchesini M, Colla S, Jin EJ, Sulman EP, Spring DJ, Yung WA, **Verhaak RGW**, Chin L, Wang YA, DePinho RA. PAF promotes stemness and radioresistance of glioma stem cells. Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):E9086-E9095. doi: 10.1073/pnas.1708122114. Epub 2017 Oct 9. PMID: 29073105; PMCID: PMC5664518.
61. Eskilsson E, Røsland GV, Solecki G, Wang Q, Harter PN, Graziani G, **Verhaak RGW**, Winkler F, Bjerkvig R, Miletic H. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. Neuro Oncol. 2018 May 18;20(6):743-752. doi: 10.1093/neuonc/nox191. PMID: 29040782; PMCID: PMC5961011.
62. Figueroa J, Phillips LM, Shahar T, Hossain A, Gumin J, Kim H, Bean AJ, Calin GA, Fueyo J, Walters ET, Kalluri R, **Verhaak RG**, Lang FF. Exosomes from Glioma-Associated Mesenchymal Stem Cells Increase the Tumorigenicity of Glioma Stem-like Cells via Transfer of miR-1587. Cancer Res. 2017 Nov 1;77(21):5808-5819. doi: 10.1158/0008-5472.CAN-16-2524. Epub 2017 Aug 30. PMID: 28855213; PMCID: PMC5668150.
63. Amin SB, **Verhaak RGW**. Navigating the Cancer Transcriptome by Decoding Divergent Oncogenic States. Cell Syst. 2017 Aug 23;5(2):90-92. doi: 10.1016/j.cels.2017.08.006. PMID: 28837814.
64. Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT; TCGA Research Network; Cherniack AD, Benz C, Mills GB, **Verhaak RGW**, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2017 Aug 14;32(2):204-220.e15. doi: 10.1016/j.ccell.2017.07.003. Erratum in: Cancer Cell. 2018 Jan 8;33(1):151. PMID: 28810145; PMCID: PMC5619925.
65. Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Sauvé CG, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, **Verhaak RGW.** Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2017 Jul 10;32(1):42-56.e6. doi: 10.1016/j.ccell.2017.06.003. Erratum in: Cancer Cell. 2018 Jan 8;33(1):152. PMID: 28697342; PMCID: PMC5599156.
66. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ; Cancer Genome Atlas Network; Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep. 2017 Jun 27;19(13):2878-2880. doi: 10.1016/j.celrep.2017.06.008. Erratum for: Cell Rep. 2017 Mar 14;18(11):2780-2794. PMID: 28658632; PMCID: PMC6141445.
67. Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu; Cancer Genome Atlas Research Network. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell. 2017 Jun 15;169(7):1327-1341.e23. doi: 10.1016/j.cell.2017.05.046. PMID: 28622513; PMCID: PMC5680778.
68. Galbán S, Al-Holou WN, Wang H, Welton AR, Heist K, Hu XK, **Verhaak RG**, Zhu Y, Espinoza C, Chenevert TL, Hoff BA, Galbán CJ, Ross BD. MRI-Guided Stereotactic Biopsy of Murine GBM for Spatiotemporal Molecular Genomic Assessment. Tomography. 2017 Mar;3(1):9-15. doi: 10.18383/j.tom.2017.00112. PMID: 28553660; PMCID: PMC5444878
69. Lu H, Villafane N, Dogruluk T, Grzeskowiak CL, Kong K, Tsang YH, Zagorodna O, Pantazi A, Yang L, Neill NJ, Kim YW, Creighton CJ, **Verhaak RG**, Mills GB, Park PJ, Kucherlapati R, Scott KL. Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer. Cancer Res. 2017 Jul 1;77(13):3502-3512. doi: 10.1158/0008-5472.CAN-16-2745. Epub 2017 May 16. PMID: 28512244; PMCID: PMC5568774.
70. Hu X, Martinez-Ledesma E, Zheng S, Kim H, Barthel F, Jiang T, Hess KR, **Verhaak RGW**. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol. 2017 Jun 1;19(6):786-795. doi: 10.1093/neuonc/now285. PMID: 28340142; PMCID: PMC5464432.
71. Schulze Heuling E, Knab F, Radke J, Eskilsson E, Martinez-Ledesma E, Koch A, Czabanka M, Dieterich C, **Verhaak RG**, Harms C, Euskirchen P. Prognostic Relevance of Tumor Purity and Interaction with MGMT Methylation in Glioblastoma. Mol Cancer Res. 2017 May;15(5):532-540. doi: 10.1158/1541-7786.MCR-16-0322. Epub 2017 Feb 1. PMID: 28148826.
72. Barthel FP, Wei W, Tang M, Martinez-Ledesma E, Hu X, Amin SB, Akdemir KC, Seth S, Song X, Wang Q, Lichtenberg T, Hu J, Zhang J, Zheng S, **Verhaak RG**. Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet. 2017 Mar;49(3):349-357. doi: 10.1038/ng.3781. Epub 2017 Jan 30. PMID: 28135248; PMCID: PMC5571729.
73. Barthel FP, Wei W, Tang M, Martinez-Ledesma E, Hu X, Amin SB, Akdemir KC, Seth S, Song X, Wang Q, Lichtenberg T, Hu J, Zhang J, Zheng S, **Verhaak RG**. Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet. 2017 Mar;49(3):349-357. doi: 10.1038/ng.3781. Epub 2017 Jan 30. PMID: 28135248; PMCID: PMC5571729
74. Bowman RL, Wang Q, Carro A, **Verhaak RG**, Squatrito M. GlioVis data portal for visualization and analysis of brain tumor expression datasets. Neuro Oncol. 2017 Jan;19(1):139-141. doi: 10.1093/neuonc/now247. Epub 2016 Nov 9. PMID: 28031383; PMCID: PMC5193031.
75. Breunig JJ, Levy R, Antonuk CD, Molina J, Dutra-Clarke M, Park H, Akhtar AA, Kim GB, Town T, Hu X, Bannykh SI, **Verhaak RGW**, Danielpour M. Ets Factors Regulate Neural Stem Cell Depletion and Gliogenesis in Ras Pathway Glioma. Cell Rep. 2016 Dec 20;17(12):3407. doi: 10.1016/j.celrep.2016.12.026. Erratum for: Cell Rep. 2015 Jul 14;12(2):258-71. PMID: 28009307.
76. Shingu T, Ho AL, Yuan L, Zhou X, Dai C, Zheng S, Wang Q, Zhong Y, Chang Q, Horner JW, Liebelt BD, Yao Y, Hu B, Chen Y, Fuller GN, **Verhaak RG**, Heimberger AB, Hu J. Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nat Genet. 2017 Jan;49(1):75-86. doi: 10.1038/ng.3711. Epub 2016 Nov 14. PMID: 27841882; PMCID: PMC5453714.
77. Rondinelli B, Rosano D, Antonini E, Frenquelli M, Montanini L, Huang D, Segalla S, Yoshihara K, Amin SB, Lazarevic D, The BT, **Verhaak RG**, Futreal PA, Di Croce L, Chin L, Cittaro D, Tonon G. Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer. J Clin Invest. 2016 Nov 1;126(11):4387. doi: 10.1172/JCI91191. Epub 2016 Nov 1. Erratum for: J Clin Invest. 2015 Dec;125(12):4625-37. PMID: 27801678; PMCID: PMC5096900.
78. Tang M, **Verhaak RG**. A Molecular Take on Malignant Rhabdoid Tumors. Trends Cancer. 2016 May;2(5):217-218. doi: 10.1016/j.trecan.2016.04.003. PMID: 27672680; PMCID: PMC5035037.
79. Pinheiro KV, Alves C, Buendia M, Gil MS, Thomaz A, Schwartsmann G, de Farias CB, Roesler R, Bowman RL, Wang Q, Carro A, **Verhaak RG**, Squatrito M. Targeting tyrosine receptor kinase B in gliomas. Neuro Oncol. 2017 Jan;19(1):138-139. doi: 10.1093/neuonc/now199. Epub 2016 Sep 14. PMID: 27630272; PMCID: PMC5193030.
80. Ferguson SD, Xiu J, Weathers SP, Zhou S, Kesari S, Weiss SE, **Verhaak RG**, Hohl RJ, Barger GR, Reddy SK, Heimberger AB. GBM-associated mutations and altered protein expression are more common in young patients. Oncotarget. 2016 Oct 25;7(43):69466-69478. doi: 10.18632/oncotarget.11617. PMID: 27579614; PMCID: PMC5342491.
81. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, Choueiri TK, Waldmann J, Mete O, Robertson AG, Wu HT, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill AJ, Sidhu SB, Almeida MQ, Fragoso MCBV, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA; Cancer Genome Atlas Research Network; Hammer GD, Giordano TJ, **Verhaak RGW**. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell. 2016 Aug 8;30(2):363. doi: 10.1016/j.ccell.2016.07.013. Epub 2016 Aug 8. Erratum for: Cancer Cell. 2016 May 9;29(5):723-36. PMID: 27505681.
82. Sircar K, Yoo SY, Majewski T, Wani K, Patel LR, Voicu H, Torres-Garcia W, **Verhaak RG**, Tannir N, Karam JA, Jonasch E, Wood CG, Tamboli P, Baggerly KA, Aldape KD, Czerniak B. Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. J Pathol Clin Res. 2015 Jul 7;1(4):212-24. doi: 10.1002/cjp2.23. PMID: 27499906; PMCID: PMC4939892.
83. **Verhaak RG.** Moving the needle: Optimizing classification for glioma. Sci Transl Med. 2016 Aug 3;8(350):350fs14. doi: 10.1126/scitranslmed.aah4740. PMID: 2748889
84. Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, **Verhaak RG**, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016 Oct;18(10):1357-66. doi: 10.1093/neuonc/now132. Epub 2016 Jul 1. PMID: 27370400; PMCID: PMC5035527.
85. Eskilsson E, **Verhaak RG**. Longitudinal genomic characterization of brain tumors for identification of therapeutic vulnerabilities. Neuro Oncol. 2016 Aug;18(8):1037-9. doi: 10.1093/neuonc/now064. Epub 2016 May 28. PMID: 27236194; PMCID: PMC4933487
86. Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, Imielinski M, Hu X, Ling S, Akbani R, Rosenberg M, Cibulskis C, Ramachandran A, Collisson EA, Kwiatkowski DJ, Lawrence MS, Weinstein JN, **Verhaak RG**, Wu CJ, Hammerman PS, Cherniack AD, Getz G; Cancer Genome Atlas Research Network; Artyomov MN, Schreiber R, Govindan R, Meyerson M. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016 Jun;48(6):607-16. doi: 10.1038/ng.3564. Epub 2016 May 9. PMID: 27158780; PMCID: PMC4884143.
87. Tang M, **Verhaak RGW**. A Molecular Take on Malignant Rhabdoid Tumors. Trends Cancer. 2016 May;2(5):217-218. doi: 10.1016/j.trecan.2016.04.003. Epub 2016 Apr 28. PMID: 28741508.
88. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG Jr, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH; TCGA Research Network; Noushmehr H, Iavarone A, **Verhaak RG**. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016 Jan 28;164(3):550-63. doi: 10.1016/j.cell.2015.12.028. PMID: 26824661; PMCID: PMC4754110
89. Tamura R, Yoshihara K, Yamawaki K, Suda K, Ishiguro T, Adachi S, Okuda S, Inoue I, **Verhaak RG**, Enomoto T. Novel kinase fusion transcripts found in endometrial cancer. Sci Rep. 2015 Dec 22;5:18657. doi: 10.1038/srep18657. PMID: 26689674; PMCID: PMC4687039.
90. Gupta SK, Kizilbash SH, Carlson BL, Mladek AC, Boakye-Agyeman F, Bakken KK, Pokorny JL, Schroeder MA, Decker PA, Cen L, Eckel-Passow JE, Sarkar G, Ballman KV, Reid JM, Jenkins RB, **Verhaak RG**, Sulman EP, Kitange GJ, Sarkaria JN. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. J Natl Cancer Inst. 2015 Nov 27;108(5):djv369. doi: 10.1093/jnci/djv369. PMID: 26615020; PMCID: PMC4862419.
91. Sathyan P, Zinn PO, Marisetty AL, Liu B, Kamal MM, Singh SK, Bady P, Lu L, Wani KM, Veo BL, Gumin J, Kassem DH, Robinson F, Weng C, Baladandayuthapani V, Suki D, Colman H, Bhat KP, Sulman EP, Aldape K, Colen RR, **Verhaak RG**, Lu Z, Fuller GN, Huang S, Lang FF, Sawaya R, Hegi M, Majumder S. Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. J Neurosci. 2015 Nov 11;35(45):15097-112. doi: 10.1523/JNEUROSCI.1265-15.2015. PMID: 26558781; PMCID: PMC4642241.
92. Rondinelli B, Rosano D, Antonini E, Frenquelli M, Montanini L, Huang D, Segalla S, Yoshihara K, Amin SB, Lazarevic D, The BT, **Verhaak RG**, Futreal PA, Di Croce L, Chin L, Cittaro D, Tonon G. Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer. J Clin Invest. 2015 Dec;125(12):4625-37. doi: 10.1172/JCI81040. Epub 2015 Nov 9. Erratum in: J Clin Invest. 2016 Nov 1;126(11):4387. PMID: 26551685; PMCID: PMC4665784.
93. Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, Caldas C, Califano A, Doherty M, Elsner M, Esteller M, Fitzgerald R, Korbel JO, Lichter P, Mason CE, Navin N, Pe'er D, Polyak K, Roberts CW, Siu L, Snyder A, Stower H, Swanton C, **Verhaak RG**, Zenklusen JC, Zuber J, Zucman-Rossi J. Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015 Aug;21(8):846-53. doi: 10.1038/nm.3915. PMID: 26248267; PMCID: PMC4785013.
94. Martinez-Ledesma E, **Verhaak RG**, Treviño V. Identification of a multi-cancer gene expression biomarker for cancer clinical outcomes using a network-based algorithm. Sci Rep. 2015 Jul 23;5:11966. doi: 10.1038/srep11966. PMID: 26202601; PMCID: PMC5378879.
95. Breunig JJ, Levy R, Antonuk CD, Molina J, Dutra-Clarke M, Park H, Akhtar AA, Kim GB, Hu X, Bannykh SI, **Verhaak RG**, Danielpour M. Ets Factors Regulate Neural Stem Cell Depletion and Gliogenesis in Ras Pathway Glioma. Cell Rep. 2015 Jul 14;12(2):258-71. doi: 10.1016/j.celrep.2015.06.012. Epub 2015 Jul 2. Erratum in: Cell Rep. 2015 Jul 21;12(3):535. Erratum in: Cell Rep. 2016 Jan 12;14(2):401. Erratum in: Cell Rep. 2016 Dec 20;17 (12 ):3407. PMID: 26146073
96. Cancer Genome Atlas Research Network; Brat DJ, **Verhaak RG**, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T Jr, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG Jr, Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, Mclendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015 Jun 25;372(26):2481-98. doi: 10.1056/NEJMoa1402121. Epub 2015 Jun 10. PMID: 26061751; PMCID: PMC4530011.
97. Geisenberger C, Mock A, Warta R, Rapp C, Schwager C, Korshunov A, Nied AK, Capper D, Brors B, Jungk C, Jones D, Collins VP, Ichimura K, Bäcklund LM, Schnabel E, Mittelbron M, Lahrmann B, Zheng S, **Verhaak RG**, Grabe N, Pfister SM, Hartmann C, von Deimling A, Debus J, Unterberg A, Abdollahi A, Herold-Mende C. Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. Acta Neuropathol. 2015 Sep;130(3):419-34. doi: 10.1007/s00401-015-1427-y. Epub 2015 May 1. PMID: 25931051
98. Kim H, **Verhaak RG**. Transcriptional mimicry by tumor-associated stroma. Nat Genet. 2015 Apr;47(4):307-9. doi: 10.1038/ng.3255. PMID: 25814306
99. Martinez-Ledesma E, de Groot JF, **Verhaak RG**. Seek and destroy: relating cancer drivers to therapies. Cancer Cell. 2015 Mar 9;27(3):319-21. doi: 10.1016/j.ccell.2015.02.011. PMID: 25759016
100. Kim H, Zheng S, Amini SS, Virk SM, Mikkelsen T, Brat DJ, Grimsby J, Sougnez C, Muller F, Hu J, Sloan AE, Cohen ML, Van Meir EG, Scarpace L, Laird PW, Weinstein JN, Lander ES, Gabriel S, Getz G, Meyerson M, Chin L, Barnholtz-Sloan JS**, Verhaak RG**. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015 Mar;25(3):316-27. doi: 10.1101/gr.180612.114. Epub 2015 Feb 3. PMID: 25650244; PMCID: PMC4352879.
101. Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, Liu W, Yang JY, Yoshihara K, Li J, Ling S, Seviour EG, Ram PT, Minna JD, Diao L, Tong P, Heymach JV, Hill SM, Dondelinger F, Städler N, Byers LA, Meric-Bernstam F, Weinstein JN, Broom BM, **Verhaak RG**, Liang H, Mukherjee S, Lu Y, Mills GB. Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun. 2015 Jan 28;6:4852. doi: 10.1038/ncomms5852. Erratum for: Nat Commun. 2014;5:3887. PMID: 25629879.
102. Yoshihara K, **Verhaak RG.** Hiding in the dark: uncovering cancer drivers through image-guided genomics. Genome Biol. 2014 Dec 20;15(12):563. doi: 10.1186/s13059-014-0563-3. PMID: 25608759; PMCID: PMC4311473.
103. Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, Vegesna R, Kim H, **Verhaak RG**. The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene. 2015 Sep 10;34(37):4845-54. doi: 10.1038/onc.2014.406. Epub 2014 Dec 15. PMID: 25500544; PMCID: PMC4468049.
104. Galvao RP, Kasina A, McNeill RS, Harbin JE, Foreman O, **Verhaak RG**, Nishiyama A, Miller CR, Zong H. Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multistep reactivation process. Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):E4214-23. doi: 10.1073/pnas.1414389111. Epub 2014 Sep 22. PMID: 25246577; PMCID: PMC4210043.
105. van Thuijl HF, Scheinin I, Sie D, Alentorn A, van Essen HF, Cordes M, Fleischeuer R, Gijtenbeek AM, Beute G, van den Brink WA, Meijer GA, Havenith M, Idbaih A, Hoang-Xuan K, Mokhtari K, **Verhaak RG**, van der Valk P, van de Wiel MA, Heimans JJ, Aronica E, Reijneveld JC, Wesseling P, Ylstra B. Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas. Genome Biol. 2014 Sep 23;15(9):471. doi: 10.1186/s13059-014-0471-6. PMID: 25245118; PMCID: PMC4195855.
106. Qiao Y, Quinlan AR, Jazaeri AA, **Verhaak RG**, Wheeler DA, Marth GT. SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization. Genome Biol. 2014 Aug 26;15(8):443. doi: 10.1186/s13059-014-0443-x. PMID: 25160522; PMCID: PMC4180956.
107. Martínez E, Yoshihara K, Kim H, Mills GM, Treviño V, **Verhaak RG**. Comparison of gene expression patterns across 12 tumor types identifies a cancer supercluster characterized by TP53 mutations and cell cycle defects. Oncogene. 2015 May 21;34(21):2732-40. doi: 10.1038/onc.2014.216. Epub 2014 Aug 4. PMID: 25088195; PMCID: PMC4317393.
108. Han L, Yuan Y, Zheng S, Yang Y, Li J, Edgerton ME, Diao L, Xu Y, **Verhaak RGW**, Liang H. The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes. Nat Commun. 2014 Jul 7;5:3963. doi: 10.1038/ncomms4963. PMID: 24999802; PMCID: PMC4339277.
109. Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, Liu W, Yang JY, Yoshihara K, Li J, Ling S, Seviour EG, Ram PT, Minna JD, Diao L, Tong P, Heymach JV, Hill SM, Dondelinger F, Städler N, Byers LA, Meric-Bernstam F, Weinstein JN, Broom BM, **Verhaak RG**, Liang H, Mukherjee S, Lu Y, Mills GB. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun. 2014 May 29;5:3887. doi: 10.1038/ncomms4887. Erratum in: Nat Commun. 2015;6:4852. PMID: 24871328; PMCID: PMC4109726.
110. Torres-García W, Zheng S, Sivachenko A, Vegesna R, Wang Q, Yao R, Berger MF, Weinstein JN, Getz G, **Verhaak RG**. PRADA: pipeline for RNA sequencing data analysis. Bioinformatics. 2014 Aug 1;30(15):2224-6. doi: 10.1093/bioinformatics/btu169. Epub 2014 Apr 1. PMID: 24695405; PMCID: PMC4103589.
111. Zheng S, Kim H, **Verhaak RGW**. Silent mutations make some noise. Cell. 2014 Mar 13;156(6):1129-1131. doi: 10.1016/j.cell.2014.02.037. PMID: 24630716.
112. Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, Aldape KD, Rosenfeld S, **Verhaak RG**, Barnholtz-Sloan JS. Molecular subtypes of glioblastoma are relevant to lower grade glioma. PLoS One. 2014 Mar 10;9(3):e91216. doi: 10.1371/journal.pone.0091216. PMID: 24614622; PMCID: PMC3948818.
113. Chudnovsky Y, Kim D, Zheng S, Whyte WA, Bansal M, Bray MA, Gopal S, Theisen MA, Bilodeau S, Thiru P, Muffat J, Yilmaz OH, Mitalipova M, Woolard K, Lee J, Nishimura R, Sakata N, Fine HA, Carpenter AE, Silver SJ, **Verhaak RG**, Califano A, Young RA, Ligon KL, Mellinghoff IK, Root DE, Sabatini DM, Hahn WC, Chheda MG. ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. Cell Rep. 2014 Jan 30;6(2):313-24. doi: 10.1016/j.celrep.2013.12.032. Epub 2014 Jan 16. PMID: 24440720; PMCID: PMC4041390.
114. Zheng S, **Verhaak RG**. Intragenic breakpoint: a marker of genome instability in glioblastoma. Cell Cycle. 2013 Dec 15;12(24):3705-6. doi: 10.4161/cc.26874. Epub 2013 Oct 21. PMID: 24145229; PMCID: PMC3905055
115. Brennan CW, **Verhaak RG,** McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L; TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell. 2013 Oct 10;155(2):462-77. doi: 10.1016/j.cell.2013.09.034. Erratum in: Cell. 2014 Apr 24;157(3):753. PMID: 24120142; PMCID: PMC3910500.
116. Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB, **Verhaak RG.** Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi: 10.1038/ncomms3612. PMID: 24113773; PMCID: PMC3826632.
117. Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, **Verhaak RG**, Yung WK, Koul D. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells. Stem Cells. 2014 Jan;32(1):301-12. doi: 10.1002/stem.1528. PMID: 24038660; PMCID: PMC3947402.
118. Li J, Lu Y, Akbani R, Ju Z, Roebuck PL, Liu W, Yang JY, Broom BM, **Verhaak RG**, Kane DW, Wakefield C, Weinstein JN, Mills GB, Liang H. TCPA: a resource for cancer functional proteomics data. Nat Methods. 2013 Nov;10(11):1046-7. doi: 10.1038/nmeth.2650. Epub 2013 Sep 15. PMID: 24037243; PMCID: PMC4076789.
119. Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H; Cancer Genome Atlas (TCGA) Research Network; Takano M, Ushijima K, Tanyi JL, Coukos G, Lu Y, Mills GB, **Verhaak RG.** Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest. 2013 Sep;123(9):3740-50. doi: 10.1172/JCI68509. Epub 2013 Aug 15. Erratum in: J Clin Invest. 2013 Dec 2;123(12):5410. PMID: 23945238; PMCID: PMC3754259.
120. Zheng S, Fu J, Vegesna R, Mao Y, Heathcock LE, Torres-Garcia W, Ezhilarasan R, Wang S, McKenna A, Chin L, Brennan CW, Yung WK, Weinstein JN, Aldape KD, Sulman EP, Chen K, Koul D, **Verhaak RG**. A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev. 2013 Jul 1;27(13):1462-72. doi: 10.1101/gad.213686.113. Epub 2013 Jun 24. PMID: 23796897; PMCID: PMC3713427.
121. Du Z, Fei T, **Verhaak RG**, Su Z, Zhang Y, Brown M, Chen Y, Liu XS. Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat Struct Mol Biol. 2013 Jul;20(7):908-13. doi: 10.1038/nsmb.2591. Epub 2013 Jun 2. PMID: 23728290; PMCID: PMC3702647.
122. Watanabe H, Francis JM, Woo MS, Etemad B, Lin W, Fries DF, Peng S, Snyder EL, Tata PR, Izzo F, Schinzel AC, Cho J, Hammerman PS, **Verhaak RG**, Hahn WC, Rajagopal J, Jacks T, Meyerson M. Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes Dev. 2013 Jan 15;27(2):197-210. doi: 10.1101/gad.203208.112. Epub 2013 Jan 15. PMID: 23322301; PMCID: PMC3566312.
123. **Verhaak RG**, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, Sougnez C, Tsherniak A, Gomez S, Onofrio R, Gabriel S, Chin L, Zhang N, Spellman PT, Zhang Y, Akbani R, Hoadley KA, Kahn A, Köbel M, Huntsman D, Soslow RA, Defazio A, Birrer MJ, Gray JW, Weinstein JN, Bowtell DD, Drapkin R, Mesirov JP, Getz G, Levine DA, Meyerson M; Cancer Genome Atlas Research Network. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013 Jan;123(1):517-25. doi: 10.1172/JCI65833. Epub 2012 Dec 21. PMID: 23257362; PMCID: PMC3533304.
124. **Verhaak RG**, Mills GB. Regulation of mRNA expression in breast cancer - a cis-tematic trans-action. Breast Cancer Res. 2012 Oct 29;14(5):322. doi: 10.1186/bcr3227. PMID: 23106814; PMCID: PMC4053097.
125. Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, Guo W, Scherer SE, Carter H, Westin SN, Dyer MD, **Verhaak RG**, Zhang F, Karchin R, Liu CG, Lu KH, Broaddus RR, Scott KL, Hennessy BT, Mills GB. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012 Nov;22(11):2120-9. doi: 10.1101/gr.137596.112. Epub 2012 Oct 1. PMID: 23028188; PMCID: PMC3483541.
126. Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, **Verhaak RG**, Lu Y, Mills GB, Slingerland JM. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res. 2012 Nov 1;18(21):5911-23. doi: 10.1158/1078-0432.CCR-12-1257. Epub 2012 Aug 15. PMID: 22896656; PMCID: PMC3698880.
127. Zong H, **Verhaak RG**, Canoll P. The cellular origin for malignant glioma and prospects for clinical advancements. Expert Rev Mol Diagn. 2012 May;12(4):383-94. doi: 10.1586/erm.12.30. PMID: 22616703; PMCID: PMC3368274.
128. Beekman R, Valkhof MG, Sanders MA, van Strien PM, Haanstra JR, Broeders L, Geertsma-Kleinekoort WM, Veerman AJ, Valk PJ, **Verhaak RG**, Löwenberg B, Touw IP. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood. 2012 May 31;119(22):5071-7. doi: 10.1182/blood-2012-01-406116. Epub 2012 Feb 27. PMID: 22371884.
129. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, Losman JA, Joensuu P, Bergmann U, Gross S, Travins J, Weiss S, Looper R, Ligon KL, **Verhaak RG**, Yan H, Kaelin WG Jr. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012 Feb 15;483(7390):484-8. doi: 10.1038/nature10898. PMID: 22343896; PMCID: PMC3656605
130. Zheng S, Chheda MG, **Verhaak RG.** Studying a complex tumor: potential and pitfalls. Cancer J. 2012 Jan-Feb;18(1):107-14. doi: 10.1097/PPO.0b013e3182431c57. PMID: 22290264; PMCID: PMC3342695.
131. Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, Sougnez C, Voet D, Saksena G, Sivachenko A, Jing R, Parkin M, Pugh T, **Verhaak RG**, Stransky N, Boutin AT, Barretina J, Solit DB, Vakiani E, Shao W, Mishina Y, Warmuth M, Jimenez J, Chiang DY, Signoretti S, Kaelin WG Jr, Spardy N, Hahn WC, Hoshida Y, Ogino S, DePinho RA, Chin L, Garraway LA, Fuchs CS, Baselga J, Tabernero J, Gabriel S, Lander ES, Getz G, Meyerson M. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011 Sep 4;43(10):964-968. doi: 10.1038/ng.936. PMID: 21892161; PMCID: PMC3802528.
132. Liu C, Sage JC, Miller MR, **Verhaak RG**, Hippenmeyer S, Vogel H, Foreman O, Bronson RT, Nishiyama A, Luo L, Zong H. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell. 2011 Jul 22;146(2):209-21. doi: 10.1016/j.cell.2011.06.014. Epub 2011 Jul 7. PMID: 21737130; PMCID: PMC3143261.
133. Kostic AD, Ojesina AI, Pedamallu CS, Jung J, **Verhaak RG,** Getz G, Meyerson M. PathSeq: software to identify or discover microbes by deep sequencing of human tissue. Nat Biotechnol. 2011 May;29(5):393-6. doi: 10.1038/nbt.1868. PMID: 21552235; PMCID: PMC3523678.
134. Winslow MM, Dayton TL, **Verhaak RG**, Kim-Kiselak C, Snyder EL, Feldser DM, Hubbard DD, DuPage MJ, Whittaker CA, Hoersch S, Yoon S, Crowley D, Bronson RT, Chiang DY, Meyerson M, Jacks T. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature. 2011 May 5;473(7345):101-4. doi: 10.1038/nature09881. Epub 2011 Apr 6. PMID: 21471965; PMCID: PMC3088778.
135. Wang XV, **Verhaak RG**, Purdom E, Spellman PT, Speed TP. Unifying gene expression measures from multiple platforms using factor analysis. PLoS One. 2011 Mar 11;6(3):e17691. doi: 10.1371/journal.pone.0017691. PMID: 21436879; PMCID: PMC3059153.
136. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, **Verhaak RG**, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K; Cancer Genome Atlas Research Network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010 May 18;17(5):510-22. doi: 10.1016/j.ccr.2010.03.017. Epub 2010 Apr 15. PMID: 20399149; PMCID: PMC2872684.
137. Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, Johnson LA, Robinson J, **Verhaak RG**, Sougnez C, Onofrio RC, Ziaugra L, Cibulskis K, Laine E, Barretina J, Winckler W, Fisher DE, Getz G, Meyerson M, Jaffe DB, Gabriel SB, Lander ES, Dummer R, Gnirke A, Nusbaum C, Garraway LA. Integrative analysis of the melanoma transcriptome. Genome Res. 2010 Apr;20(4):413-27. doi: 10.1101/gr.103697.109. Epub 2010 Feb 23. PMID: 20179022; PMCID: PMC2847744.
138. **Verhaak RG**, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010 Jan 19;17(1):98-110. doi: 10.1016/j.ccr.2009.12.020. PMID: 20129251; PMCID: PMC2818769.
139. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, **Verhaak RG**, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, Ramos AH, Woo MS, Weir BA, Getz G, Beroukhim R, O'Kelly M, Dutt A, Rozenblatt-Rosen O, Dziunycz P, Komisarof J, Chirieac LR, Lafargue CJ, Scheble V, Wilbertz T, Ma C, Rao S, Nakagawa H, Stairs DB, Lin L, Giordano TJ, Wagner P, Minna JD, Gazdar AF, Zhu CQ, Brose MS, Cecconello I, Ribeiro U Jr, Marie SK, Dahl O, Shivdasani RA, Tsao MS, Rubin MA, Wong KK, Regev A, Hahn WC, Beer DG, Rustgi AK, Meyerson M. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009 Nov;41(11):1238-42. doi: 10.1038/ng.465. Epub 2009 Oct 4. PMID: 19801978; PMCID: PMC2783775.
140. **Verhaak RG**, Valk PJ. Genes predictive of outcome and novel molecular classification schemes in adult acute myeloid leukemia. Cancer Treat Res. 2010;145:67-83. doi: 10.1007/978-0-387-69259-3\_5. PMID: 20306246.
141. **Verhaak RG**, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S, Löwenberg B, Delwel R, Valk PJ. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica. 2009 Jan;94(1):131-4. doi: 10.3324/haematol.13299. Epub 2008 Oct 6. PMID: 18838472; PMCID: PMC2625407.
142. Sanders MA, **Verhaak RG**, Geertsma-Kleinekoort WM, Abbas S, Horsman S, van der Spek PJ, Löwenberg B, Valk PJ. SNPExpress: integrated visualization of genome-wide genotypes, copy numbers and gene expression levels. BMC Genomics. 2008 Jan 25;9:41. doi: 10.1186/1471-2164-9-41. PMID: 18221515; PMCID: PMC2235842.
143. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, **Verhaak RG**, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007 Dec 6;450(7171):893-8. doi: 10.1038/nature06358. Epub 2007 Nov 4. PMID: 17982442; PMCID: PMC2538683.
144. Steidl U, Steidl C, Ebralidze A, Chapuy B, Han HJ, Will B, Rosenbauer F, Becker A, Wagner K, Koschmieder S, Kobayashi S, Costa DB, Schulz T, O'Brien KB, **Verhaak RG**, Delwel R, Haase D, Trümper L, Krauter J, Kohwi-Shigematsu T, Griesinger F, Tenen DG. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest. 2007 Sep;117(9):2611-20. doi: 10.1172/JCI30525. PMID: 17694175; PMCID: PMC1937499.
145. Wouters BJ, Jordà MA, Keeshan K, Louwers I, Erpelinck-Verschueren CA, Tielemans D, Langerak AW, He Y, Yashiro-Ohtani Y, Zhang P, Hetherington CJ, **Verhaak RG**, Valk PJ, Löwenberg B, Tenen DG, Pear WS, Delwel R. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood. 2007 Nov 15;110(10):3706-14. doi: 10.1182/blood-2007-02-073486. Epub 2007 Aug 1. PMID: 17671232; PMCID: PMC2077318
146. Bakker WJ, van Dijk TB, Parren-van Amelsvoort M, Kolbus A, Yamamoto K, Steinlein P, **Verhaak RG,** Mak TW, Beug H, Löwenberg B, von Lindern M. Differential regulation of Foxo3a target genes in erythropoiesis. Mol Cell Biol. 2007 May;27(10):3839-3854. doi: 10.1128/MCB.01662-06. PMID: 17353275; PMCID: PMC1900006.
147. Steidl U, Rosenbauer F, **Verhaak RG**, Gu X, Ebralidze A, Otu HH, Klippel S, Steidl C, Bruns I, Costa DB, Wagner K, Aivado M, Kobbe G, Valk PJ, Passegué E, Libermann TA, Delwel R, Tenen DG. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat Genet. 2006 Nov;38(11):1269-77. doi: 10.1038/ng1898. Epub 2006 Oct 15. PMID: 17041602.
148. **Verhaak RG**, Sanders MA, Bijl MA, Delwel R, Horsman S, Moorhouse MJ, van der Spek PJ, Löwenberg B, Valk PJ. HeatMapper: powerful combined visualization of gene expression profile correlations, genotypes, phenotypes and sample characteristics. BMC Bioinformatics. 2006 Jul 12;7:337. doi: 10.1186/1471-2105-7-337. PMID: 16836741; PMCID: PMC1574351.
149. **Verhaak RG**, Staal FJ, Valk PJ, Lowenberg B, Reinders MJ, de Ridder D. The effect of oligonucleotide microarray data pre-processing on the analysis of patient-cohort studies. BMC Bioinformatics. 2006 Mar 2;7:105. doi: 10.1186/1471-2105-7-105. PMID: 16512908; PMCID: PMC1481623.
150. Erkeland SJ, **Verhaak RG**, Valk PJ, Delwel R, Löwenberg B, Touw IP. Significance of murine retroviral mutagenesis for identification of disease genes in human acute myeloid leukemia. Cancer Res. 2006 Jan 15;66(2):622-6. doi: 10.1158/0008-5472.CAN-05-2908. PMID: 16423987
151. **Verhaak RG**, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, Uitterlinden AG, Erpelinck CA, Delwel R, Löwenberg B, Valk PJ. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005 Dec 1;106(12):3747-54. doi: 10.1182/blood-2005-05-2168. Epub 2005 Aug 18. PMID: 16109776
152. Valk PJ, **Verhaak RG**, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Löwenberg B, Delwel R. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004 Apr 15;350(16):1617-28. doi: 10.1056/NEJMoa040465. PMID: 15084694.